Lilly Unveils Historic $3.5 Billion Manufacturing Investment in Pennsylvania for Next-Gen Weight-Loss Medicines

Eli Lilly and Company

Eli Lilly and Company has announced a historic $3.5 billion investment to establish a state-of-the-art manufacturing campus in Fogelsville, Pennsylvania. As the largest life sciences project in the Commonwealth’s history, this facility will be dedicated to producing next-generation injectable medicines, including the investigational triple hormone receptor agonist retatrutide. The project is set to create 850 high-value jobs and solidify the Lehigh Valley as a premier global hub for pharmaceutical innovation and domestic supply chain resilience.

Pharma Giants Strike Landmark Deal with U.S. Government to Slash Drug Prices and Onshore Manufacturing

TheWhiteHouse

Major pharmaceutical leaders Novartis, Amgen, Gilead, GSK, and Sanofi have signed landmark voluntary agreements with the U.S. government to adopt “Most Favored Nation” pricing. The deal introduces the TrumpRx.gov platform for direct-to-patient savings, slashes prices for critical medications like insulin and Hep C cures, and triggers $150 billion in U.S. manufacturing investments.